GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.…
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
GRI Bio (NASDAQ: GRI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 1.120 USD on 20 November 2026, down 97.6% over 52 weeks. Its 52-week range is 1.090 USD to 64.12 USD: the price is 98.3% below the high and 2.8% above the low.
Its market capitalisation is 2.45M USD.
GRI Bio reports return on equity of -199.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 9.44M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.